Canon enters regenerative medicine with cell therapy acquisition

Manufacturer seeks to blend AI imaging with culturing tech to lower cost barriers

20230322N Stem cell lab REUTERS

A scientist prepares stem cells at a British lab. Regenerative therapy is on track to become an $11 billion market by 2028. © Reuters

TSUYOSHI TAMEHIRO and KOHEI YAMADA, Nikkei staff writers

TOKYO -- Canon is adding cell culturing to its medical business portfolio, leveraging technology from its camera business to improve efficiency in a key area for the burgeoning field of regenerative medicine.

The Japanese manufacturer has agreed to acquire the cell culture operations of packing equipment maker Kyoto Seisakusho, including its patents, for an undisclosed amount in a deal expected to be completed by mid-May.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.